ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026
ORIC Pharmaceuticals presented preclinical and translational data at ESMO Congress 2026 supporting rinzimetostat, its EED-based PRC2 inhibitor, as a way to enhance sensitivity to androgen receptor inhibition in prostate cancer. Key findings include maintained potency against EZH2-resistance mutations seen with mevrometostat, no hematologic tumorigenesis in rat toxicology (in contrast to the EZH2 inhibitor tazemetostat), and mechanistic proof-of-concept in mCRPC patient samples.
Key figures
- Drug Name
- rinzimetostat
- Phase Of Trial
- Phase 3
- Indication
- prostate cancer
- Trial name
- Himalayas-1
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.